Form 4: Sangamo Therapeutics Executive Sells Shares for Tax Obligations After RSU Vesting
SEC Form 4
Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of Sangamo Therapeutics, sold shares to cover tax obligations following the vesting of a restricted stock unit (RSU) grant.
Summary
- On April 22, 2025, Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, surrendered 31,866 shares of common stock to cover mandatory tax withholding obligations.
- The shares were surrendered at a price of $0.7763 per share, based on the issuer's closing stock price on the same date.
- This transaction was related to the vesting of a portion of a restricted stock unit (RSU) grant under the company's Amended and Restated 2018 Equity Incentive Plan.
- Following the transaction, Dubois-Stringfellow beneficially owns 801,539 shares of Sangamo Therapeutics common stock.
- These holdings include shares from previous RSU grants that are vesting in quarterly installments through January 22, 2026, February 24, 2026 and February 25, 2026.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a common transaction (tax-related stock sale). It doesn't inherently convey positive or negative sentiment.
Future Outlook
The document outlines the vesting schedule of existing RSU grants, indicating future equity compensation for the reporting person contingent on continued service.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates routine tax-related stock sales following RSU vesting, a common practice among executives.
Stakeholder Impact
- The transaction has a minor dilutive effect on existing shareholders due to the initial issuance of shares for the RSU grant, but the subsequent sale for tax purposes is unlikely to have a significant impact.
Key Dates
| Date | Description |
|---|---|
| January 22, 2024 | Date of Reporting Person's RSU grant, vesting in successive equal quarterly installments through January 22, 2026 |
| February 24, 2023 | Date of Reporting Person's RSU grant, vesting in successive equal quarterly installments through February 24, 2026 |
| February 25, 2025 | Date of Reporting Person's RSU grant, vesting as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. |
| April 22, 2025 | Date of transaction: Shares surrendered for tax withholding at $0.7763/share due to RSU vesting. |
| April 24, 2025 | Date of Form 4 filing. |
| February 25, 2026 | One-fourth (1/4) of the shares subject to the February 25, 2025 RSU grant will vest. |
Keywords
Form 4, Sangamo Therapeutics, SGMO, Nathalie Dubois-Stringfellow, RSU, Restricted Stock Unit, Tax Withholding, Beneficial Ownership, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.